
Research Article: Open Source Tools and Methods | Novel Tools and Methods

OpenVape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents

<https://doi.org/10.1523/ENEURO.0279-20.2020>

Cite as: eNeuro 2020; 10.1523/ENEURO.0279-20.2020

Received: 27 June 2020

Revised: 30 July 2020

Accepted: 18 August 2020

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2020 Frie et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Manuscript Title Page Instructions

1. Manuscript Title (50 word maximum)

OpenVape: an Open-Source E-Cigarette Vapour Exposure Device for Rodents

2. Abbreviated Title (50 character maximum)

OpenVape: an Open-Source Vapour Exposure Device

3. List all Author Names and Affiliations in order as they would appear in the published article

Jude A. Frie – Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Ontario, Canada.

Jacob Underhill – Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Ontario, Canada.

Bin Zhao – Departments of Pharmacology and Toxicology, University of Toronto, Ontario, Canada

Giordano de Guglielmo – Department of Psychiatry, University of California, San Diego, San Diego, California, USA.

Rachel F. Tyndale – Departments of Pharmacology and Toxicology, and Psychiatry, University of Toronto, Ontario, Canada; Centre for Addiction and Mental Health, Toronto, Canada.

Jibran Y. Khokhar – Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Ontario, Canada.

4. Author Contributions: JAF, JU and JYK: Designed Research, Performed research, Contributed unpublished reagents/ analytic tools, Analyzed data, Wrote the paper. BZ: Performed Research. GdG: Designed Research. RFT: Performed Research, Wrote the Paper.

5. Correspondence should be addressed to (include email address)

Dr. Jibran Khokhar
Department of Biomedical Sciences
Ontario Veterinary College
University of Guelph
50 Stone Rd. E.
Guelph, ON
N1G1C5
jkhokhar@uoguelph.ca

37

38 **6. Acknowledgements**

39 We would like to thank Judy Chen and Ariel Oren for their assistance with CPP
40 experiments.

41

42 **7. Conflict of Interest**

43

44 **A. No (State ‘Authors report no conflict of interest’)**

45

46 **B. Yes (Please explain)**

47


48 **Yes** – RF Tyndale has consulted for Quinn Emanuel and Ethismos Research Inc on
49 unrelated topics.

50 **8. Funding sources**

51 This work was supported by a Discovery Grant from the Natural Sciences and Engineering
52 Research Council award (RGPIN-2019-05121) to JYK. This research was undertaken, in
53 part, thanks to funding from the Canada Research Chairs program (RFT, CRC in
54 Pharmacogenomics) and a Canadian Institutes of Health Research (Foundation grant FDN-
55 154294).

56

57

58 **Visual Abstract**

59

60 **Abstract**

61 The prevalence of "vaping" has recently seen significant increases in North America, especially
62 in adolescents. However, the behavioural correlates of vaping are largely unexplored. The uptake
63 of existing technologies meant for rodent vapour inhalation remains limited due to a lack of
64 affordability and versatility (ability to be used with a variety of vapourizers). The OpenVape
65 offers an open-source, low-cost solution that can be used in a variety of research contexts. Here
66 we present a specific use case, combining the OpenVape apparatus with JUUL e-cigarettes. This
67 apparatus consists of Arduino-operated vacuum pumps that deliver vapour directly from e-
68 cigarettes to exposure chambers. The OpenVape is easy to build and customize for any type of
69 vapourizer (e.g., nicotine pod or tank; cannabis flower or concentrates). To test the OpenVape,
70 we performed biochemical verification and behavioural studies. The behavioural test

71 (conditioned place preference) was conducted using adolescent and adult animals to assess
72 developmental differences in the rewarding effects of nicotine vapour, as previously observed
73 with injected nicotine. These findings demonstrate that even after brief exposures to nicotine
74 vapour, pharmacologically relevant nicotine and cotinine levels could be detected in plasma, and
75 significant conditioned place preference was observed, especially in adolescent rats which
76 showed preference at shorter puff delivery durations (lower nicotine doses) compared to adults.
77 Together, these findings suggest that OpenVape provides an affordable, open-source option for
78 pre-clinical behavioural research into the effects of vaping.

79 **Significance Statement**

80 With the recent increases in popularity of vaping, behavioural and neurobiological studies in
81 preclinical models will be pivotal in exploring the impacts of this use. While there are
82 commercially available vapour exposure equipment, they can be prohibitively expensive and
83 often require proprietary software. The OpenVape (OV) is able to deliver regulated doses of
84 vapour into a standard animal cage with minimal operator intervention. The OV is also open-
85 source, easy to build, inexpensive, and can be used in a variety of research contexts due to its
86 small physical footprint. In this study, we validate its efficacy using JUUL e-cigarettes, showing
87 that animals achieve meaningful nicotine levels, and that both adolescent and adult animals
88 display conditioned place preference to the nicotine vapour.

89 **Introduction**

90 In recent years, adolescent e-cigarette use has increased dramatically, with past 30-day nicotine
91 vaping among US high school students growing from 11.7% to 27.5% between 2017 and 2019
92 (Wang et al., 2019). Currently, the most popular e-cigarette is the JUUL, maintaining 76% of the

93 US e-cigarette market (Craver, 2019). JUUL's adolescent appeal has been attributed to their
94 sleek/discreet design (Kavuluru et al., 2019). influential marketing (Mantey et al., 2016; Huang
95 et al., 2019), appealing flavours (Leavens et al., 2019), and high nicotine content (Kong et al.,
96 2019). Additionally, JUUL's have been shown to deliver significantly more nicotine to the
97 bloodstream compared to traditional cigarettes (Rao et al., 2020).

98 Adolescence is thought to be a period of increased sensitivity to the rewarding effects of nicotine
99 (Thorpe et al., 2020). Indeed, nearly 90% of cigarette smokers initiate smoking before the age of
100 18 (Substance Abuse and Mental Health Services Administration, 2013). Adolescent smokers
101 also increase cigarette intake faster than adults (DiFranza et al., 2000), and report more positive
102 and less aversive experiences to initial cigarette exposures (Benowitz, 1999) Animal studies
103 support this data, with adolescent animals consistently showing both greater preference, and
104 preference across a larger range of doses during nicotine conditioned place preference (CPP)
105 compared to adults, a measure of the reward-like (hedonic value) properties of a drug (Vastola et
106 al., 2002; Belluzzi et al., 2004; Shram et al., 2006; Brielmaier et al., 2007; Kota et al., 2007,
107 2008; Torres et al., 2008; Shram and Lê, 2010; Ahsan et al., 2014). While beneficial in
108 understanding the rewarding effects of nicotine, these studies may not capture what makes
109 nicotine vapour rewarding in adolescents. The current study improves upon the translatability of
110 findings by directly exposing rats to the most popular e-cigarette available – JUUL. No studies to
111 date have assessed the developmental differences in nicotine vapour preference, partly owing to
112 limited options for exposing rodents to nicotine vapour.

113 Current commercially available nicotine vapour exposure apparatuses (e.g. DSI Buxco, SCIREQ
114 inExpose, LJARI eVape) are prohibitively expensive and require proprietary hardware and
115 software to operate, thereby limiting their accessibility and versatility. This has led others to

116 create customized alternatives (Manwell et al., 2014; Liu et al., 2016; Nguyen et al., 2016; Hage
117 et al., 2017; Lefever et al., 2017; Hilpert et al., 2019). However, these alternatives are still very
118 expensive, complicated to construct, and are not always open-source. Thus, in order to address
119 these issues, we created OpenVape (OV) – an affordable, open-source vapour delivery system.
120 OV can be made for ~\$230, is easily constructed/operated, and is highly versatile (can be used
121 with a variety of vaping devices and products). It is also open-source, encouraging the
122 community to continue to add functionality as required. Here we provide the instructions to build
123 the simplest version of OV and provide a relevant behavioural validation showing the
124 developmental differences in nicotine’s reward-like properties during a CPP task. We also show
125 that OV is capable of producing pharmacologically relevant blood nicotine and cotinine levels
126 following short periods of vapour exposure.

127 **Materials and Methods**

128 **Animals**

129 For the pharmacokinetic study, 15 adult male Sprague (Charles River, Quebec) were used. These
130 rats were housed in pairs and given *ad libitum* access to standard chow and water. For the age-
131 dependent CPP study, a total of 48 male Sprague-Dawley rats were used, consisting of 24 adults
132 and 24 adolescents. These rats were housed in groups of 4 (to maintain consistency between
133 adult and adolescent rats) and given access to standard chow and water. All animal procedures
134 were performed in accordance with the [Author University] animal care committee's regulations.

135 **Device Design**

136 The OV device requires one standard wall receptacle for power. OV is compact and does not
 137 require extensive lab space to store or for use. The device can be built for ~\$230 CAD in parts
 138 per apparatus (**Table 1**). The simple construction and programming of this design also does not
 139 require extensive coding or electronic/circuits experience. The components required to build the
 140 OV, and the step-by-step instructions are presented below:

141 **Table 1: Bill of Materials**

Component	Quantity	Price	Source of Materials
Arduino Uno (with cable)	1	\$12.99	www.amazon.ca
JUUL Starter Pack	2	\$129.98	www.juul.ca
H-Bridge Motor Controller	1	\$1.89	www.amazon.ca
DC Vacuum Motor	2	\$45.98	www.amazon.ca
Solderless Breadboard	1	\$3.49	www.amazon.ca
AC/DC converter (with Power Jack)	1	\$13.49	www.amazon.ca
Jumper Cables	120	\$6.98	www.amazon.ca
8mm Silicone Tubing	1 (3 feet)	\$9.09	www.amazon.ca
Heat Shrink Tubing Pack	1	\$6.99	www.amazon.ca
Allentown Mouse Cages	2	-	In-Lab
3D Printed Nozzles	2	-	In-Lab
PCB (Optional) - Replaces H-Bridge, breadboard, and jumper cables	1	-	-
Total		\$230.88 (CAD)	

142

143 An Arduino microcontroller takes simple instructions from code and relays them to an H-Bridge,
144 which sends the required signals to the motors.


145 **Build Instructions**

146 Detailed step-by-step OV building instructions, Arduino code, 3D printer files, and electrical
147 layouts are all available at <https://www.khokharlab.com/open-source-file-downloads>. A brief
148 overview of the instructions is included in **Table 2** (refer to **Figure 1** and **Figure 2** for
149 clarification).


150 **Table 2:** *Build Instructions*

<i>Step</i>	<i>Instructions</i>
<i>1</i>	Download the code file from https://www.khokharlab.com/open-source-file-downloads
<i>2</i>	Print the nozzles from https://www.khokharlab.com/open-source-file-downloads using a 3D printer
<i>3</i>	Attach the H-bridge to the breadboard
<i>4</i>	Wire the Arduino to the system with six “logic” cables, a power cable, and a ground
<i>5</i>	Connect the two terminals of each motor to the corresponding H-bridge pins (Figure 2)
<i>6</i>	Insert two cables into the DC power jack (one for ground and one to power the motors)
<i>7</i>	Secure a charged and filled JUUL e-cigarette to each of the two motors with heat shrink

- 8** On the “out” ports of each motor, tightly heat shrink one end of an 8mm plastic tubes onto it
- 9** Heat shrink the 3D printed nozzles onto the opposite ends of each 8mm plastic tube and insert the nozzles into the drilled holes on the ends of each of the Allentown mouse cages
- 10** Plug the Arduino board into your computer and using the Arduino IDE, upload the appropriate code onto the board
- 11** Plug both the Arduino and the adjustable voltage supply into a receptacle. The cable to the Arduino will automatically supply the desired voltage to the board
- 12** Adjust the voltage supply to 6V and vapour clouds will appear at the specified intervals




151 **Figure 1:** Labelled schematic of the OpenVape System.



152

153 **Figure 2:** Wiring Diagram for OpenVape apparatus.

154 A custom printed circuit board (PCB) has also been included. This simplifies the construction of
155 the device as it eliminates the need for many wired connections. The small PCB is plugged into
156 the Arduino to control all logic commands. The board replaces the H-bridge, breadboard, and
157 many wired connections while increasing simplicity of construction and reducing cost even
158 further. For ease of replication the design has been included below in **Figure 3**.



159

160 **Figure 3:** Custom PCB design to facilitate building the OpenVape apparatus.

161 Code Accessibility

162 The code/software described in the paper is freely available online at
163 <https://www.khokharlab.com/open-source-file-downloads>. The code is available as Extended
164 Data.

165 Operating Instructions

166 To customize the interval time, the uploaded Arduino code must be adjusted. In the brackets
167 after “DELAY” the number of seconds (x1000) of vapour administration required can be
168 entered, followed by the seconds (x1000) of rest required. The looped code will repeat this
169 sequence forever. However, a time constraint can be set if needed. The default code pulses on for
170 2 seconds, then rests for 4 seconds. These parameters were determined through iterative
171 experimentation to be the optimum timing in order to maximize the amount of vapour produced,
172 while not overheating the JUUL device; these parameters can be modified to optimize vapour
173 delivery from other vapourizers.

174 After uploading the desired code, the system can be turned on by rotating the voltage dial to 6
175 volts. Similar to the timing parameters, this voltage setting was found to dispense the optimal
176 vapour clouds while ensuring the JUUL does not over-heat or melt the pod. The system can be
177 turned off by returning the dial to 0 volts. This setting can also be adjusted based on the
178 vapourizer used through an iterative process.

179 **JUUL-specific instructions**

180 For the specific use case with JUUL, the JUUL e-cigarette’s battery life (200 inhales) is large
181 enough for most applications but will occasionally require recharging. The battery on the JUUL
182 indicates if the power is running low by flashing red. The battery can be charged by separating
183 the JUUL from the heat shrink and placing the JUUL upright on the provided USB charger until
184 the LED glows green. The other maintenance task is replacing the JUUL pod. Conveniently, the
185 battery lasts approximately as long as the JUUL pod does, therefore, if the code provided is used,
186 the system can run at least twenty minutes without the need for recharging. The pods can be
187 replaced with a new pod or refilled for the vehicle groups. The vehicle pod can be refilled by
188 gently removing the lid of the pod and injecting the e-liquid vehicle into the pod with a syringe.

189 Drugs

190 JUUL mango 5% nicotine e-liquid (59 mg/ml) or vehicle e-liquid was administered. Vehicle e-
191 liquid was mixed based on a recent gas chromatography–mass spectrometry study that
192 established the primary JUUL mango flavor constituents (Ethyl Maltol, 3-Hexen-1-ol, Ethyl
193 butanoate, and delta-undecalactone [Advanced Biotech, New York]), and a 30:60 mixture of
194 propylene glycol and glycerol. (Omaiye et al., 2019) The dose of nicotine is determined by the
195 duration of time that the motor is running and pumping vapour into the cage (including puffs and
196 timeouts).

197 Plasma Nicotine and Cotinine Concentrations

198 Adult male rats (N=15; distinct from animals used for CPP) were divided into groups of 5, each
199 group receiving a different dose. Each group received 2, 4, or 8 minutes of pump activation;
200 thereby, altering the amount of vapour in the cage. Each epoch of pump activation produced a 2-
201 second puff duration, followed by a 4-second time-out resulting in 10 2-second puffs/minute
202 (e.g., 2-minute group received 20 2-second long puffs). Though the device only produced vapour
203 for 2, 4, or 8 minutes, all animals spent a total of 10 minutes in the chambers. Following the 2, 4,
204 or 8 minutes of pump activation (including puffs and time-outs), the device is turned off and the
205 rat is allowed to remain in the chamber for the remaining time (8, 6, and 2 minutes, respectively).
206 Thus, the time in the chamber was always 10 minutes, but the vapour concentration differed
207 based on the duration of pump activation. After one session of their respective vapour dose,
208 saphenous blood draws were conducted for each animal 10 and 120 minutes after the end of
209 exposure (20 and 130 minutes after exposure initiation). The collected blood samples were
210 centrifuged at $1400 \times g$ for ten minutes. The resulting plasma was collected and stored at -4°C .

211 LC-MS/MS analysis was used to quantify the levels of nicotine and cotinine following
212 previously published sample preparation and quantification methods (Craig et al., 2014). The
213 plasma levels were only assessed in adult male rats as a validation of the efficacy of the device in
214 delivering pharmacologically relevant doses of nicotine; the impact of age and sex on nicotine
215 vapour pharmacokinetics will be addressed in a more comprehensive manner in upcoming
216 studies from our group.

217 **Conditioned Place Preference**

218 *Dosing for Conditioned Place Preference*


219 The group of animals was divided by age (24 adult and 24 adolescent) then each age group was
220 further divided into 4 unique dosage groups. The first group was a vehicle control and was
221 exposed to the vehicle vapour on every conditioning day with a dose of 4 minutes (as a control
222 for the biased CPP design used in this paper). The remaining groups received a dose of 2, 4, or 8
223 minutes depending on the group. Whether the vapour contained nicotine or vehicle solution
224 depended on the day of the study. Cage mates were exposed together to the vapour in order to
225 avoid isolation effects but were conditioned in the CPP apparatus individually in a biased design.

226 *Apparatus*

227 The CPP apparatus has two chambers separated by a wall with a guillotine door (Shuttle Boxes
228 from Coulbourn Instruments, Allentown, Pennsylvania). Each chamber (30 cm wide and 30 cm
229 long) has plexiglass surrounding walls that stand 30 cm high. A large, clear sheet of plexiglass is
230 placed over top of the chambers. Both chambers have unique visual, tactile and olfactory cues.
231 Chamber 1 has polka dotted walls, barred floors, and a vanilla scent. Chamber 2 has pinstriped

232 walls, grated floors, and a lemon scent. An Ethovision XT system (Noldus, Netherlands) was
233 used to record the amount of time the animals spent in each chamber.

234 A biased CPP protocol was chosen as it has been suggested that this protocol is better suited to
235 assess nicotine CPP; small preferences for one chamber have been shown to play a significant
236 role in nicotine CPP development (Clarke and Fibiger, 1987; Shoaib et al., 1994; Le Foll and
237 Goldberg, 2005). The CPP procedure consists of three phases: habituation, conditioning, and
238 post-conditioning. The protocol used for CPP is described as seen in **Figure 4**.



239

240 **Figure 4:** Visual schematic outlining the CPP paradigm. Figure made using BioRender.

241 *Days 1-3: Habituation*

242 During days 1 and 2 of habituation, the guillotine door is raised, and the animals roam freely
243 through both chambers for 15 minutes. On the third day, throughout the 15-minute session, the
244 time animals spend on each side of the chamber is recorded as a baseline preference.

245 *Days 4-9: Conditioning*

246 During the conditioning phase, the guillotine door is closed, and the animals are restricted to a
247 specific side of the apparatus. After being removed from their home cages and exposed to JUUL
248 nicotine vapour for 10 minutes in the OV vapour exposure chambers, animals were then
249 individually confined to their initially non-preferred chamber of the CPP apparatus (on nicotine
250 days) for 30 minutes. Following the 10-minute exposure to the vehicle solution vapour, the
251 animals were confined to their initially preferred chamber (on vehicle exposure days). The rats
252 receive these treatments on alternating days with the nicotine/vehicle start day counterbalanced
253 across animals. The vehicle control animals received received vehicle vapour on all days and
254 were confined on alternating days to the preferred and non-preferred chambers.

255 *Day 10: Post-conditioning*

256 During the post-conditioning phase, no vapour was administered and the rats were again allowed
257 access to both chambers with the guillotine door open for 15 minutes. The time each animal
258 spent in each chamber was recorded to assess each animal's final preference.

259 **Statistical Analysis**

260 Statistics were conducted using IBM SPSS Statistics 25 and GraphPad Prism 6.0 with a random
261 (superiority) design. For CPP, a conditioning index was calculated as the difference in time
262 spend in the initially preferred chamber pre- to post-conditioning. Outliers were defined as

263 animals whose difference in time on the drug paired side was greater than 2 standard deviations
 264 from the mean. Three of the adolescent rats were deemed outliers for the CPP study and were not
 265 included in the analysis, thus a total of 45 animals were analyzed. Overall comparisons were
 266 evaluated using a two-way ANOVA (Treatment x Age or Treatment x Sex). The determination
 267 of whether conditioned place preference was established was based on Bonferroni corrected one-
 268 sample t-tests compared to a theoretical conditioning index of 0. Alpha was initially set at 0.05
 269 and was adjusted down via Bonferroni correction to account for the number of comparisons such
 270 that results were only significant if $p < 0.0125$. For plasma nicotine and cotinine, a two-way (dose
 271 x time) ANOVA was conducted followed by trend analysis for each time point.

272 Results

273 Dose-dependent plasma cotinine levels observed in adult rats exposed to nicotine vapour.

274 The results from the plasma nicotine concentration assessment are shown in **Figure 5**. Plasma
 275 nicotine levels of 26.6, 34.2, and 45.2 ng/ml were observed 10 minutes after 2-, 4-, and 8-minute
 276 nicotine vapour exposure doses, respectively. Nicotine could still be detected in the plasma 120
 277 minutes after exposure. Two-way ANOVA revealed no significant effects of time ($F_{(1, 12)} =$
 278 $1.626, p=0.226^a, \eta_p^2=0.119$; **Table 3**) or dose ($F_{(2, 12)} = 0.649, p=0.540^b, \eta_p^2=0.098$; **Table 3**) on
 279 plasma nicotine levels and no interaction was observed ($F_{(2, 12)} = 1.093, p=0.366^c, \eta_p^2=0.154$;
 280 **Table 3**).


281 **Table 3:** *Statistical Table*

	Data Structure	Type of Test	Power
a	Normal	Two-way ANOVA	0.217

b	Normal	Two-way ANOVA	0.134
c	Normal	Two-way ANOVA	0.198
d	Normal	Two-way ANOVA	0.999
e	Normal	Two-way ANOVA	0.577
f	Normal	Two-way ANOVA	0.573
g	Normal	Linear Contrast	0.713
h	Normal	One-sample t-test	0.866
i	Normal	One-sample t-test	0.996
j	Normal	One-sample t-test	1.000
k	Normal	Two-way ANOVA	0.864
l	Normal	Two-way ANOVA	0.969
m	Normal	Two-way ANOVA	0.337
n	Normal	Linear Contrast	0.935
o	Normal	One-sample t-test	0.956
p	Normal	Two-way ANOVA	0.777
q	Normal	Two-way ANOVA	0.176
r	Normal	Two-way ANOVA	0.051

282


283 As expected, plasma cotinine levels were low at 10 minutes after removal from OV chambers; an
 284 increase in cotinine levels, which was dose-related, was seen 120 minutes after nicotine vapour
 285 exposure. Two-way ANOVA revealed a significant effect of time ($F_{(1, 12)} = 29.78, p=0.0001^d$,
 286 $\eta_p^2=0.713$; **Table 3**) but not dose ($F_{(2, 12)} = 3.81, p=0.0523^c, \eta_p^2=0.389$; **Table 3**) on plasma
 287 cotinine levels. There was also no interaction between dose and time ($F_{(2, 12)} = 3.782, p=0.0533^f$,
 288 $\eta_p^2=0.387$; **Table 3**). Trend analysis revealed a linear dose trend in plasma cotinine levels 120
 289 minutes after exposure ($p=0.018^g, R^2=0.3812, \eta_p^2=0.386$; **Table 3**).



290 **Figure 5:** Plasma concentrations for nicotine (left) and cotinine (right) at 10 or 120 minutes
 291 after termination of a 10-minute total exposure session during which vapour was delivered for
 292 one of 2, 4, or 8 minutes. Data represented as mean \pm SEM. # $p < 0.0001$ 120-minute timepoint vs.
 293 10-minute timepoint. * $p < 0.05$ dose trend.

294 Developmental differences in conditioned place preference for nicotine vapour

295 The results of the age-dependent CPP experiment are shown in **Figure 6**. Significant conditioned
 296 place preference was observed in adult rats exposed to 8 minutes of nicotine vapour ($t(5) = -3.86$,
 297 $p < 0.006^h$, $\eta_p^2 = \text{Cohen's } d = 1.578$; **Table 3**), whereas adolescent rats displayed significant place
 298 preference at both the 4-minute ($t(4) = -6.41$, $p < 0.002^i$, Cohen's $d = 2.865$; **Table 3**) and 8-minute
 299 ($t(5) = -13.73$, $p < 0.00002^j$, Cohen's $d = 5.606$; **Table 3**) exposure durations. No change in place
 300 preference was observed in the vehicle exposed groups. Two-Way ANOVA revealed a
 301 significant effect of age ($F_{(1,37)} = 9.872$, $p < 0.003^k$, $\eta_p^2 = 0.211$; **Table 3**) and dose ($F_{(3,37)} =$
 302 7.098 , $p < 0.001^l$, $\eta_p^2 = 0.365$; **Table 3**) but no interaction ($F_{(3,37)} = 1.384$, $p < 0.263^m$, $\eta_p^2 =$
 303 0.101 ; **Table 3**). Adolescents also showed a significant linear dose trend ($p < 0.002^n$, $R^2 = 0.4211$,
 304 $\eta_p^2 = 0.445$; **Table 3**).



305

306 **Figure 6:** Nicotine vapour CPP in adult and adolescent (PND 30-39) rats. * $p < 0.0125$ Post- vs.
 307 Pre-conditioned (Bonferroni corrected). Data represented as mean \pm SEM.

308 **Discussion**

309 This paper describes the design of an open-source e-cigarette vapour exposure device for use
 310 with rodents. The device was tested with commercially available JUUL e-cigarettes and found to
 311 produce pharmacologically relevant plasma nicotine and cotinine levels, as well as behavioural
 312 effects in a CPP paradigm. The results of the present study provide the first evidence that brief
 313 JUUL e-cigarette vapour exposures are enough to produce CPP, and that similar to other routes
 314 of nicotine administration, nicotine vapour may have stronger reward-like properties when
 315 administered in adolescence. Although it is difficult to compare CPP results between studies due
 316 to methodological differences, the change in preference of our highest dose duration (8 minute
 317 puff exposure) appears to be roughly equivalent with those found with subcutaneous injections
 318 of 0.6 mg/kg (Torres et al., 2008). This is consistent with the plasma nicotine levels observed at
 319 the longest exposure duration, with levels roughly equivalent to the peak concentrations seen
 320 with subcutaneous injections of 0.5 mg/kg (Lefever et al., 2017). These levels are also akin to
 321 those seen in adult cigarette smokers (Matta et al., 2007). The present results help validate OV as

322 a reliable behavioural neuroscience tool for use in addiction research, highlighting its utility
323 despite the device's low cost and simple design.

324 Our behavioural findings are largely consistent with previous age-related studies on nicotine
325 CPP. Overall, the enhancement of nicotine CPP in adolescent rodents has been observed across
326 multiple studies, even with significant differences in methodology (Vastola et al., 2002; Belluzzi
327 et al., 2004; Shram et al., 2006; Brielmaier et al., 2007; Kota et al., 2007, 2008; Torres et al.,
328 2008; Shram and Lê, 2010; Ahsan et al., 2014). The specifics of these enhancements, however,
329 are not always consistent, likely owing to these methodological differences. These discrepancies
330 include the time animals spend in the conditioning chamber, number of conditioning days, time
331 between exposures, dosage, method of habituation, age of exposures, route of administration,
332 species, strain, statistical methods, chamber type (2-chamber vs. 3-chamber), and chamber
333 conditions (visual, tactile, and olfactory cues). The resulting differences in observed nicotine
334 CPP enhancements range from whether adolescent rodents permit nicotine reward (Belluzzi et
335 al., 2004; Brielmaier et al., 2007; Shram et al., 2006; Vastola et al., 2002), find nicotine
336 rewarding at lower doses (Ahsan et al., 2014; Kota et al., 2009, 2007), or find nicotine rewarding
337 at higher doses compared to adults (Torres et al., 2008). Our results are most consistent with the
338 finding that adolescents find nicotine rewarding at lower doses compared to adults, though our
339 dose never reached the point at which nicotine becomes aversive; therefore, it is unknown
340 whether the adolescent rats would have also found higher doses less aversive rewarding than
341 adult rats.

342 In the past, aerosol exposures have required commercial devices with a large footprint, that were
343 costly, complicated to operate, and incompatible with the newest forms of vaping devices
344 (Alasmari et al., 2018). To avoid these issues, some labs have employed rudimentary exposure

345 regimens such as placing animals into chambers above burning cigarettes (Liu et al., 2016), or
346 filling chambers manually by emptying bags filled with vapourized cannabis (Manwell et al.,
347 2014; Nelong et al., 2019). As these methods are inconsistent and are not compatible with
348 modern vaping devices, others have begun to develop more sophisticated vapour exposure
349 setups. The designs to date, however, are generally made for specific use cases and are expensive
350 and complicated to construct. One such design used an atomizer to create vapour, which is pulled
351 through a sealed chamber by an exhaust valve (Nguyen et al., 2016; Freels et al., 2020;
352 Montanari et al., 2020). Unfortunately, the custom interface that triggers this device and other
353 components are complex to construct and operate, and the system costs upwards of \$20,000.

354 Simpler designs have also been implemented. An e-cigarette exposure apparatus by Lefever et al.
355 (2017) is most similar to OV in its low-cost and simple construction; however, similar to the
356 previously described device, it makes use of an atomizer for vapour generation, therefore
357 limiting its use to e-liquids. OV can be used with any vapourizer and has been used with both
358 pod devices and cannabis flower vapourizers. Some custom systems have been designed to be
359 compatible with both e-cigarettes and combustible cigarettes such as that created by Hage et al.
360 (2017). While the design is similar to OV, it is more complicated, not truly open-source, and
361 more expensive. Additionally, each chamber must be calibrated before every use and some of the
362 design components are housed inside the chamber where they can potentially be damaged by
363 animals. All of OV's components are outside of the chambers, making it is impossible for the
364 animals to harm themselves or damage the device. Another apparatus can customize the air-flow
365 through the chamber, monitor the aerosol content, and control puff topography (Hilpert et al.,
366 2019). While cheaper than other commercial technologies, the full apparatus (microcontroller,

367 circuitry, non-open-source remote peristaltic pump, etc.) still costs approximately \$1200 more
368 than OV.

369 One major benefit of using our system is that it gives labs the ability to use commercially
370 available pods. This benefit is demonstrated in this study with plasma nicotine levels observed in
371 our animals (after 2-8 minutes of vapour delivery) close to those observed in previous studies
372 after 60-minutes of exposure at similar doses (Montanari et al., 2020). Importantly, the nicotine
373 levels following the 8-minute exposure duration are also similar to levels achieved by rats self-
374 administering 0.5 mg/ml nicotine e-liquid vapour in a 60-minute session (Smith et al., 2020),
375 further supporting the rewarding nature of nicotine vapour (like our CPP findings) at the plasma
376 levels reached in our study. To date, nearly all other studies testing the effects of vapourized
377 nicotine have used laboratory grade nicotine dissolved in their vehicles. While this allows for the
378 ability to adjust dosing, it does not capture the novel methods of increasing nicotine
379 bioavailability used by e-cigarette manufacturers (especially in pod-designs like JUUL; Duell et
380 al., 2019).

381 While it can be useful for many applications, our device has limitations. One limitation of our
382 design, and others', is the lack of dosage measurement. The amount of nicotine e-liquid
383 expended from the JUUL could be measured, however, a considerable amount of the vapour
384 remains in the chamber without being inhaled. The rats may also react differently during the
385 vapour administration, meaning some inhale more vapour than others, possibly leading to the
386 high variability and the lack of statistically significant differences between doses in nicotine.
387 Unfortunately, this device cannot alter the dosage based on breathing rate, nor can it account for
388 age-dependent differences in tidal volume. However, plasma nicotine levels can be measured to
389 assess the amount of nicotine absorbed by the rats as we have done in this study.

390 In conclusion, OV provides researchers with a low-cost and effective method of regulated e-
391 cigarette vapour exposure for rodents. Our open-source design also allows for replication and
392 customization. As we, and others, continue to improve methods of vapour exposure, important
393 findings regarding the neurobiological effects of vaping can be revealed. OV allows for easy
394 implementation of vapour exposure paradigms in a variety of experimental designs for the
395 behavioural neuroscience, as well as the broader science, community.

396 **References**

- 397 Ahsan, H. M., de la Peña, J. B. I., Botanas, C. J., Kim, H. J., Yu, G. Y., and Cheong, J. H.
398 (2014). Conditioned place preference and self-administration induced by nicotine in
399 adolescent and adult rats. *Biomol. Ther.* 22, 460–466. doi:10.4062/biomolther.2014.056.
- 400 Alasmari, F., Crotty Alexander, L. E., Drummond, C. A., and Sari, Y. (2018). A computerized
401 exposure system for animal models to optimize nicotine delivery into the brain through
402 inhalation of electronic cigarette vapors or cigarette smoke. *Saudi Pharm. J.* 26, 622–628.
403 doi:10.1016/j.jsps.2018.02.031.
- 404 Belluzzi, J. D., Lee, A. G., Oliff, H. S., and Leslie, F. M. (2004). Age-dependent effects of
405 nicotine on locomotor activity and conditioned place preferences in rats.
406 *Psychopharmacology (Berl)*. 174, 389–395. doi:10.1007/s00213-003-1758-6.
- 407 Benowitz, N. L. (1999). Nicotine addiction. *Prim. Care - Clin. Off. Pract.* 26, 611–31.
408 doi:10.1016/S0095-4543(05)70120-2.
- 409 Brielmaier, J. M., McDonald, C. G., and Smith, R. F. (2007). Immediate and long-term
410 behavioral effects of a single nicotine injection in adolescent and adult rats. *Neurotoxicol.*
411 *Teratol.* 29, 74–80. doi:10.1016/j.ntt.2006.09.023.
- 412 Clarke, P. B. S., and Fibiger, H. C. (1987). Apparent absence of nicotine-induced conditioned
413 place preference in rats. *Psychopharmacology (Berl)*. 92, 84–88. doi:10.1007/BF00215484.
- 414 Craig, E. L., Zhao, B., Cui, J. Z., Novalen, M., Miksys, S., and Tyndale, R. F. (2014). Nicotine

- 415 pharmacokinetics in rats is altered as a function of age, impacting the interpretation of
416 animal model data. *Drug Metab. Dispos.* 42, 1447–1455. doi:10.1124/dmd.114.058719.
- 417 Craver, R. (2019). Juul ends 2018 with 76 percent market share. *Winston-Salem J.* Available at:
418 [https://www.journalnow.com/business/juul-ends-with-percent-market-](https://www.journalnow.com/business/juul-ends-with-percent-market-share/article_6f50f427-19ec-50be-8b0c-d3df18d08759.html)
419 [share/article_6f50f427-19ec-50be-8b0c-d3df18d08759.html](https://www.journalnow.com/business/juul-ends-with-percent-market-share/article_6f50f427-19ec-50be-8b0c-d3df18d08759.html).
- 420 DiFranza, J. R., Rigotti, N. A., McNeill, A. D., Ockene, J. K., Savageau, J. A., St Cyr, D., et al.
421 (2000). Initial symptoms of nicotine dependence in adolescents. *Tob. Control* 9, 313–19.
422 doi:10.1136/tc.9.3.313.
- 423 Duell, A. K., Pankow, J. F., and Peyton, D. H. (2019). Nicotine in tobacco product aerosols: It’s
424 déjà vu all over again’. *Tob. Control* 0, 1–7. doi:10.1136/tobaccocontrol-2019-055275.
- 425 Freels, T. G., Baxter-Potter, L. N., Lugo, J. M., Glodosky, X. N. C., Wright, X. H. R., Baglot, X.
426 S. L., et al. (2020). Vaporized cannabis extracts have reinforcing properties and support
427 conditioned drug-seeking behavior in rats. *J. Neurosci.* 40, 1897–1908.
428 doi:10.1523/JNEUROSCI.2416-19.2020.
- 429 Hage, A. N., Krause, W., Mathues, A., Krasner, L., Kasten, S., Eliason, J. L., et al. (2017).
430 Comparing the effects of electronic cigarette vapor and cigarette smoke in a novel in vivo
431 exposure system. *J. Vis. Exp.* 2017. doi:10.3791/55672.
- 432 Hilpert, M., Ilievski, V., Coady, M., Andrade-Gutierrez, M., Yan, B., Chillrud, S. N., et al.
433 (2019). A custom-built low-cost chamber for exposing rodents to e-cigarette aerosol:
434 practical considerations. *Inhal. Toxicol.* 31, 399–408. doi:10.1080/08958378.2019.1698678.
- 435 Huang, J., Duan, Z., Kwok, J., Binns, S., Vera, L. E., Kim, Y., et al. (2019). Vaping versus
436 JUULing: How the extraordinary growth and marketing of JUUL transformed the US retail
437 e-cigarette market. *Tob. Control*. doi:10.1136/tobaccocontrol-2018-054382.
- 438 Kavuluru, R., Han, S., and Hahn, E. J. (2019). On the popularity of the USB flash drive-shaped
439 electronic cigarette Juul. *Tob. Control*. doi:10.1136/tobaccocontrol-2018-054259.
- 440 Kong, G., Bold, K. W., Morean, M. E., Bhatti, H., Camenga, D. R., Jackson, A., et al. (2019).

- 441 Appeal of JUUL among adolescents. *Drug Alcohol Depend.* 205.
442 doi:10.1016/j.drugalcdep.2019.107691.
- 443 Kota, D., Martin, B. R., and Damaj, M. I. (2008). Age-dependent differences in nicotine reward
444 and withdrawal in female mice. *Psychopharmacology (Berl)*. 198, 201–210.
445 doi:10.1007/s00213-008-1117-8.
- 446 Kota, D., Martin, B. R., Robinson, S. E., and Damaj, M. I. (2007). Nicotine dependence and
447 reward differ between adolescent and adult male mice. *J. Pharmacol. Exp. Ther.* 322, 399–
448 407. doi:10.1124/jpet.107.121616.
- 449 Le Foll, B., and Goldberg, S. R. (2005). Nicotine induces conditioned place preferences over a
450 large range of doses in rats. *Psychopharmacology (Berl)*. 178, 481–92. doi:10.1007/s00213-
451 004-2021-5.
- 452 Leavens, E. L. S., Stevens, E. M., Brett, E. I., Leffingwell, T. R., and Wagener, T. L. (2019).
453 JUUL in school: JUUL electronic cigarette use patterns, reasons for use, and social
454 normative perceptions among college student ever users. *Addict. Behav.* 99.
455 doi:10.1016/j.addbeh.2019.106047.
- 456 Lefever, T. W., Lee, Y. O. K., Kovach, A. L., Silinski, M. A. R., Marusich, J. A., Thomas, B. F.,
457 et al. (2017). Delivery of nicotine aerosol to mice via a modified electronic cigarette device.
458 *Drug Alcohol Depend.* 172, 80–87. doi:10.1016/j.drugalcdep.2016.12.004.
- 459 Lenoir, M., Starosciak, A. K., Ledon, J., Booth, C., Zakharova, E., Wade, D., et al. (2015). Sex
460 differences in conditioned nicotine reward are age-specific. *Pharmacol. Biochem. Behav.*
461 132, 56–62. doi:10.1016/j.pbb.2015.02.019.
- 462 Liu, X., Wang, Z., Li, T., Ni, L., Zeng, R., and Liu, C. (2016). A simplified device for exposing
463 rats to cigarette smoke. *Int J Clin Exp Med* 9, 19213–19221. Available at: www.ijcem.com/
464 [Accessed May 12, 2020].
- 465 Mantey, D. S., Cooper, M. R., Clendennen, S. L., Pasch, K. E., and Perry, C. L. (2016). E-
466 Cigarette Marketing Exposure Is Associated with E-Cigarette Use among US Youth. *J.*
467 *Adolesc. Heal.* 58, 686–690. doi:10.1016/j.jadohealth.2016.03.003.

- 468 Manwell, L. A., Ford, B., Matthews, B. A., Heipel, H., and Mallet, P. E. (2014). A vapourized
469 δ 9-tetrahydrocannabinol (δ 9-THC) delivery system part II: Comparison of behavioural
470 effects of pulmonary versus parenteral cannabinoid exposure in rodents. *J. Pharmacol.*
471 *Toxicol. Methods* 70, 112–119. doi:10.1016/j.vascn.2014.06.004.
- 472 Matta, S. G., Balfour, D. J., Benowitz, N. L., Boyd, R. T., Buccafusco, J. J., Caggiula, A. R., et
473 al. (2007). Guidelines on nicotine dose selection for in vivo research. *Psychopharmacology*
474 (*Berl*). 190, 269–319. doi:10.1007/s00213-006-0441-0.
- 475 Montanari, C., Kelley, L. K., Kerr, T. M., Cole, M., and Gilpin, N. W. (2020). Nicotine e-
476 cigarette vapor inhalation effects on nicotine & cotinine plasma levels and somatic
477 withdrawal signs in adult male Wistar rats. *Psychopharmacology (Berl)*. 237, 613–625.
478 doi:10.1007/s00213-019-05400-2.
- 479 Nelong, T. F., Jenkins, B. W., Perreault, M. L., and Khokhar, J. Y. (2019). Extended Attenuation
480 of Corticostriatal Power and Coherence after Acute Exposure to Vapourized Δ 9-
481 Tetrahydrocannabinol in Rats. *Can. J. Addict.* 10, 60–66.
482 doi:10.1097/CXA.0000000000000063.
- 483 Nguyen, J. D., Aarde, S. M., Vandewater, S. A., Grant, Y., Stouffer, D. G., Parsons, L. H., et al.
484 (2016). Inhaled delivery of Δ 9-tetrahydrocannabinol (THC) to rats by e-cigarette vapor
485 technology. *Neuropharmacology* 109, 112–120. doi:10.1016/j.neuropharm.2016.05.021.
- 486 Omaiye, E. E., McWhirter, K. J., Luo, W., Pankow, J. F., and Talbot, P. (2019). High-Nicotine
487 Electronic Cigarette Products: Toxicity of JUUL Fluids and Aerosols Correlates Strongly
488 with Nicotine and Some Flavor Chemical Concentrations. *Chem. Res. Toxicol.* 32, 1058–69.
489 doi:10.1021/acs.chemrestox.8b00381.
- 490 Rao, P., Liu, J., and Springer, M. L. (2020). JUUL and Combusted Cigarettes Comparably
491 Impair Endothelial Function. *Tob. Regul. Sci.* 6, 30–37. doi:10.18001/TRS.6.1.4.
- 492 Shoaib, M., Stolerman, I. P., and Kumar, R. C. (1994). Nicotine-induced place preferences
493 following prior nicotine exposure in rats. *Psychopharmacology (Berl)*. 113, 445–452.
494 doi:10.1007/BF02245221.

- 495 Shram, M. J., Funk, D., Li, Z., and Lê, A. D. (2006). Periadolescent and adult rats respond
496 differently in tests measuring the rewarding and aversive effects of nicotine.
497 *Psychopharmacology (Berl)*. 186. doi:10.1007/s00213-006-0373-8.
- 498 Shram, M. J., and Lê, A. D. (2010). Adolescent male Wistar rats are more responsive than adult
499 rats to the conditioned rewarding effects of intravenously administered nicotine in the place
500 conditioning procedure. *Behav. Brain Res.* 206, 240–244. doi:10.1016/j.bbr.2009.09.018.
- 501 Smith, L. C., Kallupi, M., Tieu, L., Shankar, K., Jaquish, A., Barr, J., et al. (2020). Validation of
502 a nicotine vapor self-administration model in rats with relevance to electronic cigarette use.
503 *Neuropsychopharmacology*. doi:10.1038/s41386-020-0734-8.
- 504 Substance Abuse and Mental Health Services Administration (2013). Results from the 2012
505 National Survey on Drug Use and Health : Summary of National Findings. *NSDUH Ser. H-*
506 *46, HHS*.
- 507 Thorpe, H. H. A., Hamidullah, S., Jenkins, B. W., and Khokhar, J. Y. (2020). Adolescent
508 neurodevelopment and substance use: Receptor expression and behavioral consequences.
509 *Pharmacol. Ther.* 206. doi:10.1016/j.pharmthera.2019.107431.
- 510 Torres, O. V., Natividad, L. A., Tejada, H. A., Van Weelden, S. A., and O'Dell, L. E. (2009).
511 Female rats display dose-dependent differences to the rewarding and aversive effects of
512 nicotine in an age-, hormone-, and sex-dependent manner. *Psychopharmacology (Berl)*.
513 206, 303–312. doi:10.1007/s00213-009-1607-3.
- 514 Torres, O. V., Tejada, H. A., Natividad, L. A., and O'Dell, L. E. (2008). Enhanced vulnerability
515 to the rewarding effects of nicotine during the adolescent period of development.
516 *Pharmacol. Biochem. Behav.* 90, 658–663. doi:10.1016/j.pbb.2008.05.009.
- 517 Vastola, B. J., Douglas, L. A., Varlinskaya, E. I., and Spear, L. P. (2002). Nicotine-induced
518 conditioned place preference in adolescent and adult rats. *Physiol. Behav.* 77, 107–114.
519 doi:10.1016/S0031-9384(02)00818-1.
- 520 Wang, T. W., Gentzke, A. S., Creamer, M. L. R., Cullen, K. A., Holder-Hayes, E., Sawdey, M.
521 D., et al. (2019). Tobacco Product Use and Associated Factors Among Middle and High

522 School Students — United States, 2019. *Surveill. Summ.* 68, 1–22.

523 Yazarbas, G., Keser, A., Kanit, L., and Pogun, S. (2010). Nicotine-induced conditioned place
524 preference in rats: Sex differences and the role of mGluR5 receptors. *Neuropharmacology*
525 58, 374–382. doi:10.1016/j.neuropharm.2009.10.001.

526 **Extended Data 1:** Arduino code for operating the OV's vacuum pumps.

527 **Extended Data 2:** Animated build instructions.

528 **Extended Data 3:** Video of device in operation.

529